In October 2023, after my initial biopsy, I had to ask…my urologist did not volunteer…about genomic testing.

At that time I mentioned several genomic tests; but my urologist preferred the Decipher test.

My very first MRI targeted fusion biopsy showed a clinical diagnosis of GG2 (favorable intermediate risk), so tissue from that biopsy was submitted for Decipher testing.

Studies have been done regarding the value of a Decipher biopsy test, here’s one to show your urologist (there are others):
https://pmc.ncbi.nlm.nih.gov/articles/PMC8770695/
The conclusion of this study:

“In men with newly diagnosed prostate cancer, Decipher Biopsy score is independently associated with time on AS and time to treatment failure after radical therapy (i.e. radical prostatectomy or radiotherapy). The ongoing G-MAJOR clinical trial (NCT04396808) is assessing the use of molecular classifier testing in a prospective randomized trial in favorable risk prostate cancer to further establish the clinical utility of these tests.”

My 0.22 (low risk) Decipher score and Clinical-Genomic Risk Model (Decipher GRID) assessment that I was a viable candidate for AS was an important component in my personal decision making analysis and IMHO well worth pursuing.